Cao Ke, Lu Can, Han Shuang, Zou Qiong, Li Jingjing, Xie Dingfang, He Siqi, Yu Li, Zhou Jianda, Peng Xiaowei, Cao Peiguo
Department of Oncology, The Third Xiangya Hospital, Central South University Changsha, China.
Department of Pathology, The Third Xiangya Hospital, Central South University Changsha, China.
Int J Clin Exp Pathol. 2015 Jan 1;8(1):551-9. eCollection 2015.
Girdin has been proven to play a vital role in the process of proliferation, apoptosis, and invasion in various cancer cells, yet the underlying molecular mechanism in primary hepatocellular carcinoma (HCC) has not yet been clarified. Thereafter, we performed immunohistochemistry to detect the expression of Girdin in 40 primary HCC tissues and 30 matched adjacent tissues using hepatic carcinoma tissue microarray. Our data showed that the positive expression rate of Girdin in hepatocellular carcinoma tissues was 67.5%, higher than that found in adjacent tissues of 16.7% (P < 0.05). It closely correlates to tumor size, T stage, TNM stage and Edmondson-Steiner stage (P < 0.05) of HCC patients. After specific small interfering RNA of Girdin was transfected into HepG2 and Huh7.5.1 cells, the proliferation and invasion ability of tumor cells were significantly inhibited. In summary, we suggest that the oncogenic role of Girdin could provide new molecular target for the treatment of HCC.
已证实Girdin在各种癌细胞的增殖、凋亡和侵袭过程中发挥着至关重要的作用,但原发性肝细胞癌(HCC)潜在的分子机制尚未阐明。此后,我们使用肝癌组织芯片通过免疫组织化学检测了40例原发性肝癌组织和30例配对的癌旁组织中Girdin的表达。我们的数据显示,Girdin在肝癌组织中的阳性表达率为67.5%,高于癌旁组织中的16.7%(P<0.05)。它与HCC患者的肿瘤大小、T分期、TNM分期和Edmondson-Steiner分期密切相关(P<0.05)。将Girdin特异性小干扰RNA转染到HepG2和Huh7.5.1细胞后,肿瘤细胞的增殖和侵袭能力受到显著抑制。总之,我们认为Girdin的致癌作用可为HCC的治疗提供新的分子靶点。